Bacterial proteins and metabolic enzymes

Bacterial proteins and metabolic enzymes represent a broad class of therapeutic targets that are fundamental to the development of antimicrobial agents. These targets are categorized by their role in essential prokaryotic processes, such as the synthesis of the peptidoglycan cell wall, the replication and supercoiling of DNA, and the translation of mRNA into proteins (StatPearls, 2024). By exploiting the structural differences between bacterial enzymes and human analogs—such as the bacterial 70S ribosome versus the eukaryotic 80S ribosome—pharmacological agents can achieve selective toxicity against pathogens (NCBI, 2023). Common examples of these targets include Penicillin-Binding Proteins (PBPs), DNA gyrase, and Dihydrofolate Reductase (DHFR). While these targets have historically provided a robust pipeline for anti-infectives, the rapid acquisition of resistance through horizontal gene transfer and spontaneous mutations remains a primary therapeutic challenge (Nature Reviews Microbiology, 2014). Modern drug discovery continues to explore niche metabolic pathways, such as fatty acid synthesis (FASII) and specialized secretion systems, to overcome existing resistance mechanisms (PubMed, 2022).

Other names

Bacterial enzymesProkaryotic proteinsBacterial metabolic targetsAntimicrobial targets

Inhibition of cell wall peptidoglycan cross-linking, inhibition of DNA gyrase and topoisomerase IV, binding to the 30S or 50S ribosomal subunits to inhibit protein translation, and competitive inhibition of folate synthesis enzymes.